ERBB2 and breast carcinoma: Furthermore, the dual anti-HER2 therapy with lapatinib and trastuzumab is not a current standard neoadjuvant therapy for primary HER2-positive breast cancer, so caution is needed in applying the findings from the present study to clinical practice.